Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNeuropharmacology

Two Affinity Sites of the Cannabinoid Subtype 2 Receptor Identified by a Novel Homogeneous Binding Assay

Eva Martínez-Pinilla, Obdulia Rabal, Irene Reyes-Resina, Marta Zamarbide, Gemma Navarro, Juan A. Sánchez-Arias, Irene de Miguel, José L. Lanciego, Julen Oyarzabal and Rafael Franco
Journal of Pharmacology and Experimental Therapeutics September 2016, 358 (3) 580-587; DOI: https://doi.org/10.1124/jpet.116.234948
Eva Martínez-Pinilla
Neurosciences Division (E.M.-P., M.Z., J.L.L.) and Small Molecule Discovery Platform, Molecular Therapeutics Program (O.R., J.A.S.-A., I.d.M., J.O.), Centre for Applied Medical Research, University of Navarra, Pamplona, Spain; Instituto de Neurociencias del Principado de Asturias, Departamento de Morfología y Biología Celular, Facultad de Medicina, Universidad de Oviedo, Asturias, Spain (E.M.-P.); Departament de Bioquímica i Biología Molecular, Facultat de Biología,. Universitat de Barcelona, Barcelona, Spain (I.R.-R., G.N., R.F.); Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas, Madrid, Spain (I.R.-R., G.N., J.L.L., R.F.); Instituto de Investigaciones Sanitarias de Navarra, Pamplona, Spain (J.L.L.); and Institut de Biomedicina de la Universitat de Barcelona, Barcelona, Spain (R.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eva Martínez-Pinilla
Obdulia Rabal
Neurosciences Division (E.M.-P., M.Z., J.L.L.) and Small Molecule Discovery Platform, Molecular Therapeutics Program (O.R., J.A.S.-A., I.d.M., J.O.), Centre for Applied Medical Research, University of Navarra, Pamplona, Spain; Instituto de Neurociencias del Principado de Asturias, Departamento de Morfología y Biología Celular, Facultad de Medicina, Universidad de Oviedo, Asturias, Spain (E.M.-P.); Departament de Bioquímica i Biología Molecular, Facultat de Biología,. Universitat de Barcelona, Barcelona, Spain (I.R.-R., G.N., R.F.); Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas, Madrid, Spain (I.R.-R., G.N., J.L.L., R.F.); Instituto de Investigaciones Sanitarias de Navarra, Pamplona, Spain (J.L.L.); and Institut de Biomedicina de la Universitat de Barcelona, Barcelona, Spain (R.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene Reyes-Resina
Neurosciences Division (E.M.-P., M.Z., J.L.L.) and Small Molecule Discovery Platform, Molecular Therapeutics Program (O.R., J.A.S.-A., I.d.M., J.O.), Centre for Applied Medical Research, University of Navarra, Pamplona, Spain; Instituto de Neurociencias del Principado de Asturias, Departamento de Morfología y Biología Celular, Facultad de Medicina, Universidad de Oviedo, Asturias, Spain (E.M.-P.); Departament de Bioquímica i Biología Molecular, Facultat de Biología,. Universitat de Barcelona, Barcelona, Spain (I.R.-R., G.N., R.F.); Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas, Madrid, Spain (I.R.-R., G.N., J.L.L., R.F.); Instituto de Investigaciones Sanitarias de Navarra, Pamplona, Spain (J.L.L.); and Institut de Biomedicina de la Universitat de Barcelona, Barcelona, Spain (R.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marta Zamarbide
Neurosciences Division (E.M.-P., M.Z., J.L.L.) and Small Molecule Discovery Platform, Molecular Therapeutics Program (O.R., J.A.S.-A., I.d.M., J.O.), Centre for Applied Medical Research, University of Navarra, Pamplona, Spain; Instituto de Neurociencias del Principado de Asturias, Departamento de Morfología y Biología Celular, Facultad de Medicina, Universidad de Oviedo, Asturias, Spain (E.M.-P.); Departament de Bioquímica i Biología Molecular, Facultat de Biología,. Universitat de Barcelona, Barcelona, Spain (I.R.-R., G.N., R.F.); Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas, Madrid, Spain (I.R.-R., G.N., J.L.L., R.F.); Instituto de Investigaciones Sanitarias de Navarra, Pamplona, Spain (J.L.L.); and Institut de Biomedicina de la Universitat de Barcelona, Barcelona, Spain (R.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gemma Navarro
Neurosciences Division (E.M.-P., M.Z., J.L.L.) and Small Molecule Discovery Platform, Molecular Therapeutics Program (O.R., J.A.S.-A., I.d.M., J.O.), Centre for Applied Medical Research, University of Navarra, Pamplona, Spain; Instituto de Neurociencias del Principado de Asturias, Departamento de Morfología y Biología Celular, Facultad de Medicina, Universidad de Oviedo, Asturias, Spain (E.M.-P.); Departament de Bioquímica i Biología Molecular, Facultat de Biología,. Universitat de Barcelona, Barcelona, Spain (I.R.-R., G.N., R.F.); Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas, Madrid, Spain (I.R.-R., G.N., J.L.L., R.F.); Instituto de Investigaciones Sanitarias de Navarra, Pamplona, Spain (J.L.L.); and Institut de Biomedicina de la Universitat de Barcelona, Barcelona, Spain (R.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan A. Sánchez-Arias
Neurosciences Division (E.M.-P., M.Z., J.L.L.) and Small Molecule Discovery Platform, Molecular Therapeutics Program (O.R., J.A.S.-A., I.d.M., J.O.), Centre for Applied Medical Research, University of Navarra, Pamplona, Spain; Instituto de Neurociencias del Principado de Asturias, Departamento de Morfología y Biología Celular, Facultad de Medicina, Universidad de Oviedo, Asturias, Spain (E.M.-P.); Departament de Bioquímica i Biología Molecular, Facultat de Biología,. Universitat de Barcelona, Barcelona, Spain (I.R.-R., G.N., R.F.); Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas, Madrid, Spain (I.R.-R., G.N., J.L.L., R.F.); Instituto de Investigaciones Sanitarias de Navarra, Pamplona, Spain (J.L.L.); and Institut de Biomedicina de la Universitat de Barcelona, Barcelona, Spain (R.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene de Miguel
Neurosciences Division (E.M.-P., M.Z., J.L.L.) and Small Molecule Discovery Platform, Molecular Therapeutics Program (O.R., J.A.S.-A., I.d.M., J.O.), Centre for Applied Medical Research, University of Navarra, Pamplona, Spain; Instituto de Neurociencias del Principado de Asturias, Departamento de Morfología y Biología Celular, Facultad de Medicina, Universidad de Oviedo, Asturias, Spain (E.M.-P.); Departament de Bioquímica i Biología Molecular, Facultat de Biología,. Universitat de Barcelona, Barcelona, Spain (I.R.-R., G.N., R.F.); Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas, Madrid, Spain (I.R.-R., G.N., J.L.L., R.F.); Instituto de Investigaciones Sanitarias de Navarra, Pamplona, Spain (J.L.L.); and Institut de Biomedicina de la Universitat de Barcelona, Barcelona, Spain (R.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José L. Lanciego
Neurosciences Division (E.M.-P., M.Z., J.L.L.) and Small Molecule Discovery Platform, Molecular Therapeutics Program (O.R., J.A.S.-A., I.d.M., J.O.), Centre for Applied Medical Research, University of Navarra, Pamplona, Spain; Instituto de Neurociencias del Principado de Asturias, Departamento de Morfología y Biología Celular, Facultad de Medicina, Universidad de Oviedo, Asturias, Spain (E.M.-P.); Departament de Bioquímica i Biología Molecular, Facultat de Biología,. Universitat de Barcelona, Barcelona, Spain (I.R.-R., G.N., R.F.); Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas, Madrid, Spain (I.R.-R., G.N., J.L.L., R.F.); Instituto de Investigaciones Sanitarias de Navarra, Pamplona, Spain (J.L.L.); and Institut de Biomedicina de la Universitat de Barcelona, Barcelona, Spain (R.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julen Oyarzabal
Neurosciences Division (E.M.-P., M.Z., J.L.L.) and Small Molecule Discovery Platform, Molecular Therapeutics Program (O.R., J.A.S.-A., I.d.M., J.O.), Centre for Applied Medical Research, University of Navarra, Pamplona, Spain; Instituto de Neurociencias del Principado de Asturias, Departamento de Morfología y Biología Celular, Facultad de Medicina, Universidad de Oviedo, Asturias, Spain (E.M.-P.); Departament de Bioquímica i Biología Molecular, Facultat de Biología,. Universitat de Barcelona, Barcelona, Spain (I.R.-R., G.N., R.F.); Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas, Madrid, Spain (I.R.-R., G.N., J.L.L., R.F.); Instituto de Investigaciones Sanitarias de Navarra, Pamplona, Spain (J.L.L.); and Institut de Biomedicina de la Universitat de Barcelona, Barcelona, Spain (R.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafael Franco
Neurosciences Division (E.M.-P., M.Z., J.L.L.) and Small Molecule Discovery Platform, Molecular Therapeutics Program (O.R., J.A.S.-A., I.d.M., J.O.), Centre for Applied Medical Research, University of Navarra, Pamplona, Spain; Instituto de Neurociencias del Principado de Asturias, Departamento de Morfología y Biología Celular, Facultad de Medicina, Universidad de Oviedo, Asturias, Spain (E.M.-P.); Departament de Bioquímica i Biología Molecular, Facultat de Biología,. Universitat de Barcelona, Barcelona, Spain (I.R.-R., G.N., R.F.); Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas, Madrid, Spain (I.R.-R., G.N., J.L.L., R.F.); Instituto de Investigaciones Sanitarias de Navarra, Pamplona, Spain (J.L.L.); and Institut de Biomedicina de la Universitat de Barcelona, Barcelona, Spain (R.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Endocannabinoids act on G protein–coupled receptors that are considered potential targets for a variety of diseases. There are two different cannabinoid receptor types: ligands for cannabinoid type 2 receptors (CB2Rs) show more promise than those for cannabinoid type 1 receptors (CB1Rs) because they lack psychotropic actions. However, the complex pharmacology of these receptors, coupled with the lipophilic nature of ligands, is delaying the translational success of medications targeting the endocannabinoid system. We here report the discovery and synthesis of a fluorophore-conjugated CB2R-selective compound, CM-157 (3-[[4-[2-tert-butyl-1-(tetrahydropyran-4-ylmethyl)benzimidazol-5-yl]sulfonyl-2-pyridyl]oxy]propan-1-amine), which was useful for pharmacological characterization of CB2R by using a time-resolved fluorescence resonance energy transfer assay. This methodology does not require radiolabeled compounds and may be undertaken in homogeneous conditions and in living cells (i.e., without the need to isolate receptor-containing membranes). The affinity of the labeled compound was similar to that of the unlabeled molecule. Time-resolved fluorescence resonance energy transfer assays disclosed a previously unreported second affinity site and showed conformational changes in CB2R forming receptor heteromers with G protein–coupled receptor GPR55, a receptor for l-α-lysophosphatidylinositol. The populations displaying subnanomolar and nanomolar affinities were undisclosed in competitive assays using a well known cannabinoid receptor ligand, AM630 (1-[2-(morpholin-4-yl)ethyl]-2-methyl-3-(4-methoxybenzoyl)-6-iodoindole), and TH-chrysenediol, not previously tested on binding to cannabinoid receptors. Variations in binding parameters upon formation of dimers with GPR55 may reflect decreases in binding sites or alterations of the quaternary structure of the macromolecular G protein–coupled receptor complexes. In summary, the homogeneous binding assay described here may serve to better characterize agonist binding to CB2R and to identify specific properties of CB2R on living cells.

Footnotes

    • Received May 5, 2016.
    • Accepted June 27, 2016.
  • E.M.-P., O.R., J.L.L., J.O., and R.F. contributed equally to this work.

  • This research was supported by the University of Navarra Foundation for Applied Medical Research [Intramural Funds], the Spanish Ministry of Economy and Competitiveness [Grants SAF212-039875-C02-01 and BFU2012-37907; Grants PTQ-11-04781 and PTQ-11-04782 from Inncorpora-Torres Quevedo funds], and the Fundació La Marató de TV3 [Grants 20141330 and 20141331].

  • dx.doi.org/10.1124/jpet.116.234948.

  • ↵Embedded ImageThis article has supplemental material available at jpet.aspetjournals.org.

  • Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 358 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 358, Issue 3
1 Sep 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Two Affinity Sites of the Cannabinoid Subtype 2 Receptor Identified by a Novel Homogeneous Binding Assay
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNeuropharmacology

Underscoring Two CB2R Affinity Sites

Eva Martínez-Pinilla, Obdulia Rabal, Irene Reyes-Resina, Marta Zamarbide, Gemma Navarro, Juan A. Sánchez-Arias, Irene de Miguel, José L. Lanciego, Julen Oyarzabal and Rafael Franco
Journal of Pharmacology and Experimental Therapeutics September 1, 2016, 358 (3) 580-587; DOI: https://doi.org/10.1124/jpet.116.234948

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNeuropharmacology

Underscoring Two CB2R Affinity Sites

Eva Martínez-Pinilla, Obdulia Rabal, Irene Reyes-Resina, Marta Zamarbide, Gemma Navarro, Juan A. Sánchez-Arias, Irene de Miguel, José L. Lanciego, Julen Oyarzabal and Rafael Franco
Journal of Pharmacology and Experimental Therapeutics September 1, 2016, 358 (3) 580-587; DOI: https://doi.org/10.1124/jpet.116.234948
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Substituted Tryptamine Activity at 5-HT Receptors and SERT
  • KRM-II-81 Analogs
  • VTA muscarinic M5 receptors and effort-choice behavior
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics